|
|
Volumn 351, Issue 4, 2004, Pages 317-319
|
|
The price tag on progress - Chemotherapy for colorectal cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CAPECITABINE;
CETUXIMAB;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
MONOCLONAL ANTIBODY;
OXALIPLATIN;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
COLORECTAL CANCER;
COST BENEFIT ANALYSIS;
CYTOTOXICITY;
DRUG COST;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LAW;
MEDICARE;
METASTASIS;
PRIORITY JOURNAL;
REVIEW;
SYSTEMIC THERAPY;
HEALTH CARE AND PUBLIC HEALTH;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAMPTOTHECIN;
COLORECTAL NEOPLASMS;
DRUG COSTS;
HUMANS;
MEDICARE;
NEOPLASM METASTASIS;
UNITED STATES;
|
|
EID: 3242686833
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJMp048143 Document Type: Review |
|
Times cited : (391)
|
|
References (0)
|
